A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.

ABSTRACT:

Introduction

This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse intrinsic pontine glioma (DIPG).

Methods

Biweekly bevacizumab (10 mg/kg) and irinotecan (125 mg/m²) were combined with daily erlotinib. Two cohorts received increasing doses of erlotinib (65 and 85 mg/m²) following a 3 + 3 dose-escalation schedule, until disease progression with a maximum of one year. Dose-limiting toxicities (DLT) were monitored biweekly. Secondary progression free survival (sPFS) and overall survival (OS) were determined based on clinical and radiological response measurements. Quality of lif

SUBMITTER: El-Khouly FE 

PROVIDER: S-EPMC8211596 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature